SEOUL - Samsung Biologics Co. disclosed its first-quarter earnings on Wednesday, reporting a net profit of 179.4 billion won (US$131 million), which is a 26.5 percent increase from the same period last year.
According to Yonhap News Agency, operating profit for the quarter climbed to 221.3 billion won, up from 191.7 billion won a year earlier, with sales rising by 31.3 percent to 946.9 billion won. The results surpassed market expectations, as the average net profit estimate by analysts was 177.4 billion won, based on a survey conducted by Yonhap Infomax.